Wednesday, 18th November International Celiac Disease Symposium 2026

• New Prospective Insights from TEDDY - Daniel Agardh
• Lessons from the ASK Study - Marisa Stahl
• PFAS in early life and risk of celiac disease: Results from two Scandinavian cohorts - Ketil Stordal
• INTERIM RESULTS FROM TWO ONGOING PRIMARY PREVENTION TRIALS IN CHILDREN AT GENETIC RISK OF CELIAC DISEASE: THE PRECISE AND GRAIN STUDIES - Carin Andrén Aronsson
• Functional characterization of the celiac disease risk gene PUS10 identifies a novel regulator of epithelial inflammatory programming - Ainara Castellanos-Rubio

• CD19 B cell Depletion in Celiac Disease and Other Autoimmune Diseases - Chris Goodnow
• Rheumatoid Arthritis: Translational Lessons for Celiac Disease - Ranjeny Thomas

• A Duodenal Pre Gluten-Challenge Interferon-γ/Antigen-Presentation State Predicts Susceptibility to Gluten-Induced Mucosal Injury in Celiac Disease - Aline Pesi
• Using cryo-electron tomography and volume electron microscopy methods to localize active transglutaminase 2 and define the ultrastructure of dendritic cells and the small intestine - Krystal Brodsky
• Less than half of patients newly positive for tissue transglutaminase antibodies undergo upper endoscopy for diagnostic confirmation: A population-based study from Alberta, Canada - James A King
• JAK inhibition suppresses interferon driven epithelial stress pathways in celiac disease - Veera Räkköläinen
• Serum proteomic profiling of celiac disease: Extending inflammatory signatures with the novel Protein XI multiplex platform - Jostein H. Ibsen
• Global Preparedness of Celiac disease from the lens of dietitians: Are we ready for the future? - Suyasha Gupta
• Tryptophan restores AhR signaling in celiac disease: A double-blinded randomized placebo-controlled exploratory study. - Utkarshini Kirtikar
• Is prenatal exposure to per- and polyfluoroalkyl substances (PFAS) a risk factor for celiac disease? - Christina Elise Holm-Larsen
• Functional Insights into Agathobacter rectalis Strain-Level Variation in Celiac Disease - Hanna Simpson

• EVQ-001, a NanoDisc Antigen-Specific Immune Tolerance Therapy for Celiac Disease - Weston Daniel
• In Vivo Evaluation of a Multi-Epitope Gliadin Peptide Construct as a Novel Drug Substance Candidate for Epicutaneous Immunotherapy (EPIT) in Celiac Disease - Tobias L Freitag
• Safety and Efficacy of TAK-101: Results from a Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Phase 2 Trial in Patients with Celiac Disease on a Gluten-Free Diet - Jocelyn A Silvester
• Clinical, histologic and safety outcomes of ZED1227 treatment in symptomatic celiac disease patients: results from the phase 2b CEC-004/CEL randomized clinical trial - Swee Lin Chen Yi Mei
• Optimising Coeliac Disease Trials Through Participant-Centred Design: Motivators, Preferences and Gluten Challenge Acceptability - Amalia Marino
•  Study with Single Doses of VTP-1000, an Antigen-Specific Immunotherapy, Demonstrates Favorable Safety and Pharmacodynamic Responses in Adults with Confirmed Celiac Disease - Leon MD Hooftman
• Real-World Functional, Economic, and Behavioral Burden of Acute Gluten Exposure in U.S. Adults with Celiac Disease: Insights from a Large National Cohort - Marilyn Geller

Chugai Pharmaceutical, a member of the Roche Group, is a research-based company headquartered in Japan that leverages advanced antibody engineering technologies to drive innovative drug discovery.

In this presentation, we will introduce DONQ52, an investigational multispecific antibody being developed for celiac disease, currently conducting a Phase 2 clinical trial. DONQ52 is designed to selectively bind HLA-DQ2.5–gluten peptide complexes, thereby inhibiting gluten-specific T-cell activation, a key driver of celiac disease pathogenesis. This mechanism enables targeted intervention in the immune response to gluten without inducing systemic immunosuppression.

We will disclose, for the first time, the clinical results on the clinical development program for DONQ52. Following completion of Phase 1 single- and multiple-ascending-dose studies, a biological proof-of-concept (bPoC) trial is currently underway in patients with celiac disease using a controlled gluten challenge model. The study is designed to evaluate the biological activity of DONQ52 in the context of gluten exposure and to further characterize its clinical development potential.

Beyond the scientific and clinical updates, we will highlight Chugai’s holistic commitment to the celiac disease therapeutic area. We will share our overarching vision for delivering this innovative therapy to patients through active collaboration with Patient Advocacy Groups and key stakeholders, emphasizing our dedication to working hand-in-hand with the global celiac disease community.

Presented by Dr Daniel Leffler. 

Daniel Leffler, MD, MS, AGAF is a gastroenterologist caring for patients with celiac disease and other gastrointestinal disorders and is a founding member of the Celiac Center at Beth Israel Deaconess Medical Center. He is an Associate Professor of Medicine at Harvard Medical School, has received multiple National Institute of Health, foundation and industry sponsored grants and has published over 200 articles in peer reviewed literature. Dr. Leffler served as the Global Clinical Lead for Celiac Disease at Takeda Pharmaceuticals from 2016 to 2025. He is now the Global Project Strategy Lead at Chugai Pharma and the Head of the Celiac Disease DONQ52 Program.

Invite only.

• Transglutaminase and B Cells in Celiac Disease Pathogenesis - Ludvig Sollid
• Mechanisms of Tissue Damage - Bana Jabri
• Single Cell Omics and Gluten-Specific T cells in Celiac Disease - Nicole La Gruta
• A predisposing effect of HLA class II genes in celiac disease by skewing the naive CD4⁺ T-cell receptor repertoire - Ida Lindeman
• A dual role for IFNγ in epithelial injury and crypt hyperplasia in celiac disease - Joram Mooiweer
• High resolution spatial transcriptomics reveals changes in barrier function and stromal-epithelial-immune interactions in celiac disease - Karolina Künnapuu

• A Clinical Approach to NRCD - Joseph Murray
• Revising Definitions of NRCD and RCD - Fabiana Zingone
• Emerging Therapeutics for RCD - Gerhard Bouma
• Beyond the binary: shared clonal and molecular drivers link RCD1 and RCD2 in refractory coeliac disease - Anaïs Levescot
•  Intestinal Stem Cell Niche Dynamics in Celiac Disease: Implications of Gluten-Free-Diet Response. - Lalita Dr Mehra
• Functional screening of candidate antigens that may be driving the expansion of CD8⁺ T-cell clones with lymphoma driver mutations in type I refractory celiac disease  - Jennifer M Chen

• Engaging the Celiac Patient in Research and Clinical Trials - Marilyn Geller
• Patient Burden of Celiac Disease - Debra Silberg
• What Do Celiac Patients Really Want from Their Doctors and Researchers? - Heidi Urwin

• Celiac Disease in Latin America - Fernando Chirdo
• Coeliac disease in the Asia Pacific - Govind K Makharia
• Celiac Disease in Africa - Chris JJ Mulder
• Celiac Disease in the Middle East - Mohamed Shiha

• Bone Mineral Density Is Associated With Body Composition in Children With Celiac Disease   - Carina Beel
• Consolidating coeliac disease as an academic field in a Brazilian public university: trajectory, training and scientific output - Fabiana Botelho
• Defining Specialist Dietetic Care in Coeliac Disease: A National Expert Protocol - Cristian Costas
• Inadequate nutritional intake in newly diagnosed celiac disease patients starting the gluten-free diet: a question of quality and quantity? - Maxim D'heedene
• Creating Celiac-Friendly Schools: Enhancing Environments for Children's Health - Shanaz Daneshdoost
• NUTRITIONAL STATUS AND DIETARY HABITS ACROSS THE CELIAC SPECTRUM - Valentina Discepolo
• Ultra-Processed Food Intake, Fat Mass, and Gluten Exposure in Adolescents with Celiac Disease - Nan Du
• GF-NOURISH: Impact of Nutrition Education on Fruit and Vegetable Intake and Diet Quality in Pediatric Celiac Disease - Nan Du
• International Food Regulations on Oats in Gluten-Free Diets: Implications for Australia. - Kim B Faulkner-Hogg
• REDUCING DELAYS IN PAEDIATRIC COELIAC DISEASE DIAGNOSIS AND MANAGEMENT: A DIETITIAN-LED CLINIC PILOT  - Julia M Fox
• Comorbid Pediatric ARFID and Celiac Disease: A Scoping Review  - Aanya V. Gupta
• Virtual Culinary Medicine Programming Is An Effective Educational Tool For Individuals With Celiac Disease  - Anne Lee
• Implementation of the Celiac Disease Food Insecurity Resource Network (CD-FIRN): A Multi-Center Program Integrating Food Insecurity Screening with Gluten-Free Food Assistance  - Anne Lee
• Improving Knowledge and Confidence in Individuals Managing Celiac Disease Through a Dietitian-Led Virtual Education Program  - Anne Lee
• Misdiagnosed or Missed? The Gluten Diet Dilemma, Diagnostic Barriers, and Malnutrition Overlap in Paediatric Celiac Disease in Africa - Esther E.P Oyesade
• Beyond Western Guidelines: A Policy Framework for Integrating Indigenous Grains in Celiac Disease Management Across Low- and Middle-Income Countries (LMICs) - Henry D. Oyoyo
• Nutritional knowledge as a determinant of gluten-free diet quality in adults with celiac disease: An ongoing cross-sectional study - Gesala Perez-Junkera
• What Do Newly-Diagnosed Patients Want to Know About the Gluten-Free Diet? - Catherine L Raber
• A genetic toolkit to reduce Celiac Disease immunogenicity in wheat - Maria G Rottersman
• Dietary and Financial Management Challenges Among Canadian Gluten-Free Consumers - Melissa Secord
• Diet-Related Burden of Celiac Disease - Debra G. Silberg
• Gluten-free foods do not show uniform nutritional disadvantages across categories but consistently remain more expensive - Fabiana Torma Botelho
• Celiac Disease–Related Seropositivity Among Adults with Autoimmune Diseases at an Indonesian National Referral Hospital - Murdani Abdullah
• A Pilot Study of a Culturally Sensitive AI-Supported Health Education Framework for Celiac Disease Awareness in Kigali, Rwanda - Abimbola R Akinyemi
• BODY DENSITY AND METABOLIC LOAD IN THE PROGRESSION OF POTENTIAL CELIAC DISEASE - Valentina Discepolo
• Early-Life Residential Greenspace and Celiac Disease Seroconversion in a Prospective Cohort of Genetically At-Risk US Children - Nan Du
• Celiac Disease in Sub-Saharan Africa: A Scoping Review of an Underrecognized and Underdiagnosed Condition - Clement Elam
• Dermatologic and nutritional burden of celiac disease in Nepal: Cutaneous markers, micronutrient deficiency and quality of life in a low‑resource tertiary setting - Mandeep Joshi
• Is Coeliac Disease Truly Rare in Sub-Saharan Africa?; Uncovering the Evidence and Diagnostic Gaps Behind an Apparent Low Burden - Maimuna Kamilu Adamu
• Residential greenness and vegetation associated with celiac disease - Jesper Lexner
• Celiac Disease Is Associated With Increased Risk of MASLD Independent of Body Mass Index: A Large US Propensity-Score Matched Study   - Stephanie M Moleski
• AI-Driven Risk Prediction for Early Detection and Prevention of Coeliac Disease - Hafiz Mukhtar Musa
• Population screening in Norway: Who are detected by screening compared to routine care? - Ketil Stordal
• Engagement in Celiac Disease Screening and Research among Latinos in an Underserved Community - Amelie Therrien
• Non-responsive Celiac Disease and the Use of Budesonide - Patricia Bierly
• The predictors of histological responders in celiac disease after following a gluten-free diet   - Rok Seon Choung
• Non-Response to Gluten-Free Diet Beyond 12 Months in Celiac Disease: Etiologies and Prevalence of Refractory Celiac Disease. - Lalita Dr Mehra
• Ex-vivo enteroid model reveal distinct epithelial regeneration deficits and DNA damage signatures in untreated and gluten-free diet non-responsive celiac disease patients. - Lalita Dr Mehra
• Efficacy of Budesonide in Refractory Celiac Disease: A Systematic Review and Meta-analysis - Kailash Mani Pokhrel
• Addressing the Psychological Impact of Refractory Coeliac Disease: A Feasibility Study of an Online Psychological Intervention   - Rose-Marie Satherley
• Long term follow up of persistent villous atrophy despite gluten free diet after diagnosis of coeliac disease - Jeremy Woodward
• Serum calprotectin reflects underlying enteropathy and predicts negative TG3 antibody seroconversion in Dermatitis Herpetiformis - Olga Albo
• Budd Chiari syndrome in 5 children with Celiac Disease: Complete resolution on Gluten Free Diet!! - SADHNA BHASIN
• SERONEGATIVE CELIAC DISEASE: IS  IT A MARKER OF SEVERE/ EXTRAINTESTINAL DISEASE? - Raghav Lal
• Inflammatory biomarkers and physical/psychiatric symptoms in Non-celiac gluten sensitivity - Mikuni Motoyama
• Prevalence of Epilepsy in Patients with Celiac Disease: A Systematic Review and Meta-Analysis - Rukesh Yadav
• Increased Anti-Gliadin IgG Seropositivity in Patients with Low-Weight Eating Disorders: A Case-Control Study   - Hisashi Yamada
• RUXOLITINIB IN TYPE II REFRACTORY COELIAC DISEASE: FIRST CASE SERIES WITH LONG-TERM CLINICAL AND IMMUNOLOGICAL RESPONSE - Luca LE Elli
• Preclinical and Phase 1 Clinical Studies of HB-2121, A Novel Transglutaminase 2 Inhibitor for Celiac Disease - Nielsen Q. Fernandez Becker
• Barriers and Strategies for Recruitment and Retention in Celiac Disease Clinical Trials: Insights From a Mixed-Methods Analysis of U.S. Research Sites - Marilyn Geller
• A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DONQ52 in Celiac Disease Patients (the DQB101US study) - Joseph A Murray
• Validation of TG2 Inhibition in a Humanized Mouse Model vs Patients Reveals Comparable Immune and Histologic Protection from Gluten Challenge in Celiac Disease - Aline Pesi
• Design and In Vitro Validation of a Multi-Epitope Peptide Construct as a Novel Drug Substance Candidate Adapted to Epicutaneous Immunotherapy (EPIT) in Celiac Disease - Amy K Russell
• Decentralized vs in-clinic study visits: a survey of celiac disease clinical trial participants - Dory Sample
• TAK-101 immunomodulation of gliadin T and B cell responses in HLA-DQ8 mice – spleen cell targeted gene expression profiling (NanoString) and gliadin-specific IgG1/IgG2c ELISpot - Sazzad Shahrear
• The Road to Insurance Coverage for Celiac Disease Therapeutics: Identifying Critical Gaps Before Market Approval - Vanessa Weisbrod
• MICROBIOTA-INDUCED EPITHELIAL BARRIER AND POLARITY DEFECTS – MECHANISMS TRIGGERING THE DEVELOPMENT OF COELIAC DISEASE? - Michael Schumann
• Beyond Serology: microRNAs as Emerging Biomarkers for Earlier, Non Invasive Diagnosis of Pediatric Celiac Disease     - Erioluwa Aregbesola
• Diagnostic accuracy of serological testing strategies for biopsy-free diagnosis of coeliac disease: an individual patient data meta-analysis   - Katie V Charlwood
• Celiac Insider: A multilingual digital platform to support earlier diagnosis of celiac disease - Bianca den Drijver
• IL-2 release in sera of children with treated CeD upon gluten challenge - Carmen Gianfrani
• Are tissue transglutaminase IgA results reliable at the 10x upper limit of normal? An important clinical decision point in diagnosing paediatric no-biopsy coeliac disease - Shaun SC Ho
• Reducing invasive diagnosis in children at increased risk of developing coeliac disease: real-world application of ESPGHAN non-biopsy criteria - Sasha Mealing
• Early Healthcare Pathways to Celiac Disease Diagnosis in Childhood: A Population-Based Cohort Study - Sonya Meyer
• Diagnostic Yield, Clinical Misclassification, and Diagnostic Accuracy of Serology for Celiac Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis - Henry Demian Oyoyo
• Are We Meeting NASPGHAN Biopsy Recommendations? A Quality Improvement Project - Catherine L Raber
• Assessing histologic change in serial celiac duodenal biopsies using routine pathology practices: Factors affecting accuracy and interobserver reliability. - Marie Robert
• Self-reported practice and real-world histopathology documentation reveal variation in coeliac disease biopsy assessment - Gillian Skardoon
• UTILITY OF ROUTINE IGA-TISSUE TRANSGLUTAMINASE SCREENING IN FRACTURE CARE: A PROSPECTIVE EVALUATION OF 1200 ADULTS - Ajay M Verma
• Celiac Disease in Vietnam and Southeast Asia: Diagnostic Challenges, Unmet Needs, and Opportunities for Earlier Recognition - Thong Duy Vo
• The utility of flow cytometry in the diagnosis of coeliac disease - Jeremy Woodward
• Expanded Multiplex Point-of-Care Screening Reveals Frequent Non-Classical Gluten-Related Antibody Reactivity in Ethiopian Children with Type 1 Diabetes - Patricia Wusterhausen

A Duodenal Pre Gluten-Challenge Interferon-γ/Antigen-Presentation State Predicts Susceptibility to Gluten-Induced Mucosal Injury in Celiac Disease - Aline Pesi

Using cryo-electron tomography and volume electron microscopy methods to localize active transglutaminase 2 and define the ultrastructure of dendritic cells and the small intestine - Krystal Brodsky

Less than half of patients newly positive for tissue transglutaminase antibodies undergo upper endoscopy for diagnostic confirmation: A population-based study from Alberta, Canada - James A King

JAK inhibition suppresses interferon driven epithelial stress pathways in celiac disease - Veera Räkköläinen

Serum proteomic profiling of celiac disease: Extending inflammatory signatures with the novel Protein XI multiplex platform - Jostein H. Ibsen

Global Preparedness of Celiac disease from the lens of dietitians: Are we ready for the future? - Suyasha Gupta

Tryptophan restores AhR signaling in celiac disease: A double-blinded randomized placebo-controlled exploratory study. - Utkarshini Kirtikar

Is prenatal exposure to per- and polyfluoroalkyl substances (PFAS) a risk factor for celiac disease? - Christina Elise Holm-Larsen

Functional Insights into Agathobacter rectalis Strain-Level Variation in Celiac Disease - Hanna Simpson

EVQ-001, a NanoDisc Antigen-Specific Immune Tolerance Therapy for Celiac Disease - Weston Daniel

In Vivo Evaluation of a Multi-Epitope Gliadin Peptide Construct as a Novel Drug Substance Candidate for Epicutaneous Immunotherapy (EPIT) in Celiac Disease - Tobias L Freitag

Safety and Efficacy of TAK-101: Results from a Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Phase 2 Trial in Patients with Celiac Disease on a Gluten-Free Diet - Jocelyn A Silvester

Clinical, histologic and safety outcomes of ZED1227 treatment in symptomatic celiac disease patients: results from the phase 2b CEC-004/CEL randomized clinical trial - Swee Lin Chen Yi Mei

Optimising Coeliac Disease Trials Through Participant-Centred Design: Motivators, Preferences and Gluten Challenge Acceptability - Amalia Marino

Study with Single Doses of VTP-1000, an Antigen-Specific Immunotherapy, Demonstrates Favorable Safety and Pharmacodynamic Responses in Adults with Confirmed Celiac Disease - Leon MD Hooftman

Real-World Functional, Economic, and Behavioral Burden of Acute Gluten Exposure in U.S. Adults with Celiac Disease: Insights from a Large National Cohort - Marilyn Geller

A New Mouse Model for Celiac Disease: Constitutive TG2 Activation Cooperates with Gluten and HLA-DQ2 to Induce Celiac-Like Enteropathy - Fu-Chen Yang

• Challenges in Pediatric Celiac Diagnosis - Jernej Dolinsek
• Endoscopic tools, VCE, & artificial intelligence in coeliac diagnosis - Luca Elli
• T cell diagnostics - coeliac disease and beyond - Robert Anderson
• Accuracy of New European Adult Guidelines for Serology-Based Diagnosis of Celiac Disease in a United States Population - Claire Jansson-Knodell
• Beyond Anti-tTG: Multiplex Neo-Epitope Serology Improves Pediatric Celiac Disease Diagnosis and Supports Biopsy Avoidance - Patricia Wusterhausen
• Predicting celiac disease enteropathy using novel non-invasive protein biomarkers - Diksha Dr. Jha